Manish Raisinghani joins the Patient Empowerment Program to discuss how Target ALS fosters collaboration between academia and industry to research and accelerate the fight against ALS. Target ALS has funded over 50 collaborative projects. Greater than 50% of which have had an industry partner and over 60% have resulted in an ongoing drug discovery program. From their Innovative Ecosystem, 6 clinical trials have emerged. Target ALS’ commitment to fight all forms of ALS, no matter how rare, is evident in their founding support of Silence ALS, an initiative that aligns Columbia University and n-Lorem to offer an integrated solution to identify, support and potentially treat nano-rare ALS patients. Target ALS hopes that one day, no patient, no matter how rare their form of ALS, is left behind.  On This Episode We Discuss:  Target ALS’ innovative model Accelerating ALS research through collaboration  How a single nano-rare study can inform the ALS research landscapeThe importance of understanding the fundamental biology behind ALS Committing to fight all forms of ALSTarget AlS’ support for n-Lorem and Columbia University’s Silence ALS Initiative